Search

everythinglearnresearchcommunity

for

Search:↓

A female with PCOS and androgenetic alopecia is starting treatment with oral Minoxidil, topical Minoxidil 5% with finasteride, and plans to add mesotherapy. She previously tried anti-androgenic contraceptive pills but couldn't tolerate them and is using Myo Inositol for weight management.

PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.

A 29-year-old man had a successful hair transplant at Dr. Ulusan Clinic in Izmir, Turkey, receiving over 4600 grafts and exosome injections. He started using finasteride and minoxidil daily a month after shaving his head, which improved his confidence and outlook on life.

Using dutasteride anally as a hair loss treatment, with humorous and satirical comments on its effects and implications.

The conversation is about whether testing for free DHT is necessary before starting Finasteride for hair loss, despite having other hormone tests available. One person suggests that genetic response to DHT is more important than DHT levels and advises starting Finasteride without the free DHT test.

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

Finasteride users cannot donate blood due to potential risks to pregnant women, requiring a one-month cessation before donating. Dutasteride requires a six-month deferral, and topical applications are not restricted.

The user stopped finasteride while trying to conceive and switched to oral minoxidil, ketoconazole shampoo, minoxidil foam, tretinoin, and microneedling. They are considering dutasteride mesotherapy but are unsure of its safety during conception.

Kintor's Pyrilutamide results for hair loss treatment will be released soon. The treatment may replace current treatments like finasteride and minoxidil without systemic side effects.

A user shared his experience of having two healthy children while continuously using finasteride (Fin) for hair loss, challenging fears about its potential impact on fetal development. The discussion that followed included various perspectives, with some users sharing similar experiences, others expressing concerns about potential risks, and some emphasizing the need for more substantial evidence before drawing conclusions.

27-year-old female experiences aggressive hair thinning and hirsutism despite normal testosterone levels. Spironolactone and 2% minoxidil were ineffective; high DHEA sulfate levels may be the cause.

A user noticed watery semen and decreased volume after a week of using finasteride and asked if taking Zinc, pygeum, and lecithin supplements would affect finasteride's effectiveness. The conversation is about the side effects of finasteride and potential supplements to counteract them.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

PP405 shows promise for hair regrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.

Transitioning genders humorously suggested for hair regrowth, noting some transgender individuals experience this. Discusses treatments like minoxidil, finasteride, and hormone therapy, but advises against transitioning solely for hair regrowth.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

A 20-year-old male experienced significant hair regrowth after 6 months using oral dutasteride, topical minoxidil, and tretinoin. He noted side effects like occasional watery semen, lower libido, better erections, and no more acne.

The user has been taking dutasteride for 8 months and finasteride before that, with normal DHT levels but high estradiol and prolactin, leading to sexual side effects. The user is disappointed with these results.

The user is dissatisfied with their hair transplant results from Asli Tarcan, citing poor donor area management and insufficient graft density. They advise against opting for cheaper procedures and express hope for future hair cloning solutions.

Switching from finasteride to dutasteride led to significant hair regrowth and thickening for the user, who also uses ketoconazole shampoo. The user experienced increased libido and encourages others not to be discouraged by negative opinions about dutasteride.

The user experienced hair regrowth after four months of using finasteride, dutasteride, and oral minoxidil. They noted increased oiliness in their hair after starting the treatment.

The user is concerned about patchy hair regrowth after 5.5 months of treatment. They are questioning if more hair growth can be expected in the upcoming months.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

The user has been using finasteride, minoxidil, and a derma stamp for hair loss for nearly three months and is considering adding tretinoin. They are advised to be patient, as results typically take 6-12 months, and are exploring other options like oral minoxidil and dutasteride.

Finasteride users discuss potential side effects, including Post Finasteride Syndrome (PFS), with varying opinions on its legitimacy and impact. Some users report side effects like changes in semen consistency and reduced pre-ejaculate, while others emphasize the rarity and reversibility of side effects.

Men discussing hair loss treatments, including bicalutamide, cyproterone acetate, dutasteride, minoxidil, and RU58841. They share experiences and concerns about side effects like infertility, liver health, and feminization.

The conversation is about the release of Phase 3 trial results for pyrilutamide in China for treating hair loss. The user is inquiring if the actual results have been posted, noting that a recent release did not contain them.

The conversation discusses a five-year study on dutasteride, a medication for male hair loss. The study found that 89.9% of patients saw improvement or prevention of hair loss progression, with varying success rates based on different balding patterns. Side effects were mostly sexual and decreased over time. Dutasteride was concluded to be a long-term, safe, and effective treatment for male hair loss.

A user applied pyrilutamide for 6 months without hair regrowth and is considering stopping due to cost and lack of results. Another user suggests switching to finasteride, which is cheaper and has shown regrowth for them.